Shots: The P-III MEASURE 1 and FUTURE 1 study involves assessing of Cosentyx (secukinumab) 75/ 150 mg vs PBO @16 wks. or 24 wks. in patients with PsA and AS respectively P-III MEASURE 1 (N=606) and FUTURE 1(N= 371) study results: improvement in ASAS 20 (74% @75mg, 82% @150mg), improvement in signs and symptoms of […]Read More
Shots: Amgevita will be launched in 28 EU countries as well as Norway, Iceland and Liechtenstein making it 3rd EU Amgen’s approved biosimilar EMA approved Amgevita in RA, PsA, AS, nr-axSpA, plague psoriasis, HS, non-infectious panuveitis, CD and UC in adults and CD, plague psoriasis, ERA and JIA in pediatric patients Amgevita is an IgG1 […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
